ArticleGalen medical journal2025
Oral Health Related Quality of Life and Xerostomia in Cardiovascular Patients : OHRQoL in Cardiac Patients.
Article in Galen medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cardiovascular patients frequently suffer from xerostomia and several modalities has been tried to alleviate the symptom. Improving Oral Health Related Quality of Life (OHRQoL) is a subjective index and considered as the final achievement in oral treatments. The aim of the present study was to evaluate OHRQoL in these patients, as well as its relation to xerostomia and some other factors. Materials and Methods: In this cross-sectional study, 244 patients participated. OHRQoL was assessed by Oral Health Impact Profile 14 (OHIP-14). Xerostomia severity was quantified by the Xerostomia Inventory (XI). Consumed anti-hypertensive drugs, age and gender were also recorded. Data were analyzed using SPSS 22 (IBM version 22.0, Chicago, USA) and statistical significance level was considered P0.05. Results: The mean age of participants was score of OHIP-14 was 58.90 ± 5.66 years, of whom 53% were male and 47% female. The mean total OHIP-14 score was 13.33 ± 11.11. Patients with xerostomia consisted 78% of the sample, with a mean XI score of 23.9 ± 5.1. Total and all domain scores of OHIP-14 were directly and significantly correlated with XI score (P0.001). Also, age had a direct and significant correlation with both OHIP-14 (P0.001) and XI (P=0.001) scores. Use of cardiovascular drugs was not significantly related to xerostomia presence or severity (P0.05). Conclusion: The majority of cardiovascular patients suffer from moderate xerostomia, regardless to the type of medication they consume. Xerostomia affects OHRQoL in these patients and should be treated properly to improve their life quality, especially among the elderly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.